Optimizing NSCLC Treatment: Potential of ADCs Targeting HER2, HER3, and TROP-2

Content Format:

Video

Credit Type:

AMA

Credits:

1.50
A Year in Review: ADCs Targeting HER2 in NSCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
Unpacking the Potential of HER3-Targeted Therapy in NSCLC

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Current Considerations for Adverse Event Management With HER3-Directed Agents

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Congress to Clinic: Continual Evolution of HER3-Targeting in NSCLC With Expert Perspectives on Clinical Advances and Practical Application

Content Format:

Slideset

Credit Type:

--

Credits:

--
Exploring the Clinical Landscape of Novel HER3-Targeted Treatments for Advanced NSCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
Antibody‒Drug Conjugates Targeting TROP-2 in NSCLC: A Look to the Future

Content Format:

Slideset

Credit Type:

--

Credits:

--
Managing the Toxicities of TROP-2 Antibody‒Drug Conjugates in Lung Cancer

Content Format:

Video

Credit Type:

--

Credits:

--
Managing the Toxicities of TROP2 Antibody–Drug Conjugates in Lung Cancer

Content Format:

PDF

Credit Type:

--

Credits:

--
An Overview of ADCs: Key Structural Features and Potential Adverse Events

Content Format:

Slideset

Credit Type:

--

Credits:

--
Evolution of TROP2-Targeted ADCs in Solid Tumors

Content Format:

Slideset

Credit Type:

--

Credits:

--
HER3 as a Target for ADCs: Rationale and Clinical Evidence

Content Format:

Slideset

Credit Type:

--

Credits:

--